Journal article
Molecular markers of artemisinin resistance during falciparum malaria elimination in Eastern Myanmar
AM Thu, AP Phyo, C Pateekhum, JD Rae, J Landier, DM Parker, G Delmas, W Watthanaworawit, ARD McLean, A Arya, A Reyes, X Li, O Miotto, K Soe, EA Ashley, A Dondorp, NJ White, NP Day, TJC Anderson, M Imwong Show all
Malaria Journal | BMC | Published : 2024
Open access
Abstract
Background: Artemisinin resistance in Plasmodium falciparum threatens global malaria elimination efforts. To contain and then eliminate artemisinin resistance in Eastern Myanmar a network of community-based malaria posts was instituted and targeted mass drug administration (MDA) with dihydroartemisinin-piperaquine (three rounds at monthly intervals) was conducted. The prevalence of artemisinin resistance during the elimination campaign (2013–2019) was characterized. Methods: Throughout the six-year campaign Plasmodium falciparum positive blood samples from symptomatic patients and from cross-sectional surveys were genotyped for mutations in kelch-13—a molecular marker of artemisinin resistan..
View full abstractGrants
Awarded by Bill and Melinda Gates Foundation
Funding Acknowledgements
The authors would like to acknowledge the hard work and support of all members of the METF and MAM, collaborators and colleagues who have contributed to this work. NJW is a Principal Research Fellow funded by the Wellcome Trust (092956/Z/10/C). For the purpose of Open Access, the author has applied a CC BY public copyright license to any Author Accepted Manuscript version arising from this submission.